Comparison of high-performance liquid chromatography and polyclonal fluorescence polarization immunoassay for the monitoring of midazolam in the plasma of intensive care unit patients

Therapeutic Drug Monitoring

Volumn 18, Issue 5, 1996, Pages 610-619

  Bourget, P ^a   Bouton, V ^a   Lesne Hulin, A ^a   Amstutz, P ^b   Benayed, M ^c   Benhamou, D ^c   Dufieux, P L ^d   Goursot, G ^d   Grosbuis, S ^e   Haberer, J P ^f   Jardin, F ^g   Kirstetter, P ^h   Marty, J ^h   Mercatello, A ⁱ   Page, B ^g   Pourriat, J L ^j   Vassal, T ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b HÔPITAL SAINT ANTOINE   (France)

^c Hop Antoine Béclère ^*  (France)

^d Hopital Saint Michel   (France)

^e CENTRE HOSPITALIER DE VERSAILLES   (France)

^f HÔTEL DIEU   (France)

^g HÔPITAL AMBROISE PARÉ   (France)

^h BEAUJON HOSPITAL   (France)

ⁱ EDOUARD HERRIOT HOSPITAL   (France)

^j AVICENNE HOSPITAL   (France)

more..

Author keywords

Fluorescence polarization; High performance liquid chromatography; Hydroxymidazolam; Intensive care unit patients; Midazolam

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; MIDAZOLAM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG METABOLISM; DRUG MONITORING; DRUG STRUCTURE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEDATION;

ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS REACTIONS; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; HYPNOTICS AND SEDATIVES; INTENSIVE CARE; MALE; MIDAZOLAM; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 10144240353     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199610000-00015     Document Type: Article

References (28)

1. Crevat-Pisano P, Dragna S, Granthil C, et al. Plasma concentrations and pharmacokinetics of midazolam during anaesthesia. J Pharm Pharmacol 1986;38:578-82.
2. Allonen H, Ziegler G, Klotz U. Midazolam kinetics. Clin Pharmacol Ther 1981;30:653-61.
3. Smith MT, Eadie MJ, O'Rourke-Brophy T. The pharmacokinetics of midazolam in man. Eur J Clin Pharmacol 1981;19:271-8.
4. Heizmann P, Eckert M, Ziegler WH. Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharmacol 1983;16:43S-6S.
5. 14Cmidazolam in humans following oral dosing. Arzneimittelforschung 1981;31:2220-3.
6. Bauer TM, Ritz R, Haberthür C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet 1995;346:145-7.
7. Bornemann LD, Min BH, Crews T, et al. Dose dependent pharmacokinetics of midazolam. Eur J Clin Pharmacol 1985; 29:91-5.
8. Persson P, Nilsson A, Hartvig P, Tamsen A. Pharmacokinetics of midazolam in total I.V. anaesthesia. Br J Anaesth 1987;59:548-56.
9. Kanto J, Aaltonen L, Himberg JJ, Hovi-Viander M. Midazolam as an intravenous induction agent in the elderly: a clinical and pharmacokinetics study. Anesth Analg 1986;65: 15-20.
10. Mandema JW, Tuk B, Van Steveninck AL, et al. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers, Clin Pharmacol Ther 1992;51:715-28.
11. Ziegler WH, Schalch E, Leishman B, Eckert M. Comparison of the effects of intravenously administered midazolam, triazolam and their hydroxy metabolites. Br J Clin Pharmacol 1983;16:63S-9S.
12. Crevoisier CH, Ziegler WH, Eckert M, Heizmann P. Relationship between plasma concentration and effect of midazolam after oral and intravenous administration. Br J Clin Pharmacol 1983;16:51S-61S.
13. Dirksen MSC, Vree TB, Drussun JJ. Clinical pharmacokinetics of long-term infusion of midazolam in critically ill patients: preliminary results. Anaesth Intens Care 1987;4: 440-4.
14. Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia 1987;42:619-26.
15. Oldenhof H, De Jong M, Steenhoek A, Janknegt R. Clinical pharmacokinetics of midazolam in intensive care patients: a wide interpatient variability? Clin Pharmacol Ther 1988;43: 263-9.
16. Malacrida R, Fritz ME, Suter PM, Crevoisier CH. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1992;20:1123-6.
17. Reference removed from proof.
18. Crevoisier CH, Ziegler WH, Heizmann P, Dubuis R. Relationship between plasma concentration and effect of midazolam in healthy volunteers. Ann Fr Anesth Reanim 1984; 3:162-7.
19. Heizmann P, Von Alten R. Determination of midazolam and its α-hydroxymethyl metabolite in plasma by gas chromatography with electron capture detector. J High Res Chromatograph 1981;6:266-9.
20. Vree TB, Baars AM, Booij LHD, Driessen JJ. Simultaneous determination and pharmacokinetics of midazolam and its hydroxymetabolites in plasma and urine of man and dog by means of high-performance liquid chromatography. Arzneimittelforschung 1981;31:2215-9.
21. Rubio F, Miwa BJ, Garland WA. Determination of midazolam and two metabolites of midazolam in human plasma by gas chromatography-negative chemical-ionization mass spectrometry. J Chromatogr 1982;233:157-65.
22. Granthil C, Crevat-Pisano P, Bouffier C, Dragna S, Quilichini D, Coassolo P. Détermination des taux plasmatiques et pharmacocinétique du midazolam administré de façon sequentielle en cours d'anesthésie générale. Ann Fr Anesth Reanim 1985;4:84a-5a.
23. Puglisi CV, Pao J, Ferrara FJ, De Silva JA. Determination of midazolam (Versed) and its metabolites in plasma by highperformance liquid chromatography. J Chromatogr 1985; 344:199-209.
24. Ha HR, Rentsch KM, Kneer J, Vonderschmitt DJ. Determination of midazolam and its α-hydroxy metabolite in human plasma and urine by high-performance liquid chromatography. Ther Drug Monit 1993;15:338-43.
25. Jolley ME, Stroupe SD, Schwenzer KS, et al. Fluorescence polarization immunoassay. III. An automated system for therapeutic drug determination, Clin Chem 1981;27:1575-9.
26. Adamczyk M, Fishpaugh J, Harrington C, et al. Immunoassay reagents for psychoactive drugs. II. The method for the development of antibodies specific to imipramine and desipramine. J Immunol Meth 1993;163:187.
27. Popelka S, Miller D, Holen J, Kelso D. Fluorescence polarization immunoassay. II. Analyzer for rapid, precise measurement of fluorescence polarization with use of disposable cuvettes, Clin Chem 1981;27:1198.
28. Profenid (kétoprofène). Technical documentation. Paris: SPECIA Laboratories.